In this issue:
Abatacept and cardiovascular disease in RA
JAK Inhibitor discontinuation rates
Determinants in achieving target urate levels
Withdrawing abatacept and tocilizumab
Effect of body mass on RA treatment responses
Cancer risk in idiopathic inflammatory myopathies
Subtherapeutic hydroxychloroquine and SLE
RANKL blockade for erosive OA
Stair climbing and mortality in patients with OA
Steroids and SLE
Please login below to download this issue (PDF)